Targeting Major Advances in Treatment of CNS Disorders
Relmada Therapeutics addresses areas of high unmet needs in depression, CNS and ophthalmological disorders.
Who We Are
Relmada Therapeutics, Inc. is a clinical stage, publicly traded biotechnology company, developing dextromethadone (REL-1017) as a rapid-acting oral treatment for depression, CNS and ophthalmological disorders.
Novel NMDA receptor antagonist in Phase 2 clinical testing for the treatment of depression, and preclinical development for Rett syndrome and other indications.
Our efforts are guided by highly experienced drug development leadership and world-class scientific advisors that provide the expertise to efficiently advance product development.
